ASCOT Trial

AustralaSian COVID-19 Trial: A clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic.

[ASCOT Trial @ascot_trial]

Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS‐CoV‐2 infection - @ascot_trial Internal Medicine Journal https://t.co/YVMLXXmOYT

[Doherty Institute @TheDohertyInst]

Congratulations to @ascot_trial team for being awarded the Australian Clinical Trials Alliance (@ACTA_org) STInG Excellence in Trial Statistics Award, in recognition of advancing clinical practice & improving patient lives 👏
https://t.co/Db3yYRnVfs
@TheRMH @UniMelbMDHS @syctong

[Doherty Institute @TheDohertyInst]

Could #nafamostat, an antiviral drug, help treat COVID-19? @ascot_trial - a study into treatment effectiveness in patients hospitalised with COVID-19 - published results of their #antiviral research in @NEJMEvidence
https://t.co/7IwDMgel55
@TheRMH @UniMelbMDHS #COVID19

[Ian Marschner @IanMarschner]

We developed a reporting framework for adaptive clinical trials. It uses the embedded fixed designs within an adaptive trial, which yield unbiased concurrently randomised cohorts. Paper is out in @BMJMedicine

@ascot_trial
@TrialsCentre
@austrim_cre

https://t.co/Zb0i44surT

[Joshua Davis @Josh_S_Davis]

Does TMPRSS 2 inhibition improve outcomes from COVID requiring hospitalisation? Some intriguing data from the @ascot_trial @susanmorpeth @syctong @justin_denholm
https://t.co/yJihOzFjLm

[Doherty Institute @TheDohertyInst]

Interested in joining a #COVID clinical trial as a Consumer Representative? @ascot_trial is seeking two consumer advisors who have either been hospitalised with #COVID19, or supported a person hospitalised with COVID-19 (family member/carer), to join their Steering Committee.

[NEJM Evidence @NEJMEvidence]

Starting NOW: @ascot_trial investigators answer questions on trial design, statistical methods used, and more. Join here: https://t.co/810BPtE7Dp

[ASCOT Trial @ascot_trial]

Please join ASCOT CIs, @syctong & @ZoeMcquilten, for a #TwitterSpaces event hosted by @NEJMEvidence about how the @ascot_trial changed the Anticoagulation Domain to adapt to new evidence about #anticoagulation strategies for COVID-19.

[NEJM Evidence @NEJMEvidence]

Wondering how to adapt a trial when new data come out midway through it? The ASCOT Team did this for Covid-19 #anticoagulation strategies. Learn about the @ascot_trial design on #TwitterSpaces with @ZoeMcquilten & @syctong on 01/25 at 3PM EST. Sign up: https://t.co/810BPtE7Dp

[NEJM Evidence @NEJMEvidence]

In hospitalized non-critically ill pts w/ Covid-19...there was an 86% posterior prob that intermed-dose, 65% posterior prob that low-dose + aspirin, and a 7% posterior prob that therapeutic-dose AC ⬇️ the odds of death or requirement for organ support. https://t.co/uKVSidWe6t

[ASCOT Trial @ascot_trial]

ASCOT CI @ZoeMcquilten presenting the results of the Anticoagulation Domain at #ASH22. Go Zoe!

[Erica Wood @erica_m_wood]

Congratulations @ZoeMcquilten, @syctong and all @ascot_trial study investigators, sites, staff and supporters
Anticoagulation domain results presented at #ASH22 today, and just published in @NEJMEvidence
https://t.co/6rQXaGyVC5

[Doherty Institute @TheDohertyInst]

AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of blood thinning treatment needed for patients hospitalised with #COVID19, published in @NEJMEvidence
https://t.co/ZRr37GCfbZ
@ascot_trial @TheRMH @UniMelbMDHS @MonashUni @georgeinstitute #anticoagulant

[The George Institute for Global Health @georgeinstitute]

AustralaSian COVID-19 Trial #ASCOT shows the most efficient level of anti-clotting treatment for patients hospitalised w/ #COVID19

#ASCOT is a collaborative int'l study across 🇦🇺🇮🇳🇳🇵🇳🇿 led by @TheDohertyInst @georgeinstitute @MonashUni @MMClinTrials

➡️ https://t.co/83L5kZrY38

[ASCOT Trial @ascot_trial]

Read the thread below from ASCOT CI @syctong explaining the outcomes and importance of the results in our recent publication in @NEJMEvidence ⬇⬇⬇

[ASCOT Trial @ascot_trial]

The results from the Anticoagulation Domain have been published in @NEJMEvidence showing intermediate dose anticoagulation had an 86% probability of being better than low dose in non-critically ill patients with COVID-19. ➡https://t.co/Uxk1frpqSQ

[NEJM Evidence @NEJMEvidence]

In this RCT, investigators compared low-, intermediate-, and therapeutic-dose anticoagulation, as well as low-dose plus aspirin, in a diverse group of patients with Covid-19 in high-, low-, and middle-income countries. https://t.co/uKVSidWe6t

#IDTwitter #ARDS #CriticalCare

[Erica Wood @erica_m_wood]

Well done @ZoeMcquilten - great #ASH22 presentation on behalf of @aspree_org CHIP team @Monash_SPHPM: effect of clonal haematopoiesis of indeterminate potential & aspirin on clinical outcomes in healthy elderly in the ASPREE RCT
Additional information in #ASH22 abstract #3865

[ASCOT Trial @ascot_trial]

Interesting that the #RECOVERYtrial has now added the diabetes drug #empagliflozin to the platform. The mechanism of potential benefit is unclear and the DARE-3 trial was negative https://t.co/Fya07MWPr1

[Doherty Institute @TheDohertyInst]

Australia needs a prioritised national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. New in @theMJA from @AshaBowen @syctong @Josh_S_Davis

https://t.co/hJ3mSx3aut

@UniMelbMDHS @TheRMH @telethonkids @MenziesResearch

[ASCOT Trial @ascot_trial]

A couple of our ASCOT investigators in the media today explaining COVID illness and treatments.

@Josh_S_Davis on ABC PM: https://t.co/py0vN639ab

And @syctong in The Age:
https://t.co/b7tM1RbaTu

[The Royal Melbourne Hospital @TheRMH]

"Michael now has blood clots, kidney damage, high blood pressure, nerve damage and fatigue.

He had none of these conditions prior to COVID."

Watch Michael's journey on 'Cracking COVID', featuring @TheDohertyInst, on ABC tonight at 8.30pm.

https://t.co/uRb7bS7mCU

[ASCOT Trial @ascot_trial]

And funders, including: @APPRISE_CRE @macquarie Group Foundation @BHPFoundation @RBWHFoundation @minderoo @HRCNewZealand @PrattIndustries Foundation

[ASCOT Trial @ascot_trial]

The ASCOT trial has reached 600 patients!
596 from India.

The currently active domain is assessing different levels of anticoagulation

Critical for COVID trials to be conducted in low and middle income settings

[ASCOT Trial @ascot_trial]

Huge thanks to all those involved.
- Patients, doctors, nurses, research staff
- collaborators @georgeinstitute @UQ_News @HMRIAustralia
- sponsor @UniMelb @TheDohertyInst
- ethics committee @TheRMH